Zoetis Braces for Weak Vet Visits, Bets on New Products for Growth

Zoetis (NYSE:ZTS) is planning for continued pressure on veterinary visits and competition, while looking to product launches in the coming years to drive growth, Chief Financial and Operating Officer Jay Saccaro said at a company event in London.

Saccaro, who joined Zoetis about three months ago, said his review of the company’s financials, operations, customers and pipeline had largely confirmed his initial view of the business. He identified product innovation as its biggest opportunity, alongside manufacturing cost reductions and more targeted promotions.

Planning for a Pressured Market

Zoetis is not assuming an improvement in the market trends affecting its business as it plans for the remainder of the year and 2027, Saccaro said. He estimated that overall U.S. veterinary visits fell 3% to 4% in the third quarter, with dermatology-related visits down by a similar amount. Flea, tick and heartworm visits declined about 10%, he said.

Saccaro cited higher veterinary service costs, changing purchasing preferences among younger pet owners and housing affordability as near-term pressures. He also pointed to long-term support for the business from the bond between people and their pets and demand for protein.

In the third quarter, Zoetis’ pricing declined by roughly one percentage point or slightly more, while volume was flat, Saccaro said. He added that revenue met or slightly exceeded the company’s expectations.

Most promotions involved temporary rebates, discounts or incentives, although Zoetis made permanent price adjustments to Convenia and Cerenia in response to competition, he said. Dermatology market share losses moderated from about seven percentage points in the second quarter to four points in the third, while the company defended share in parasiticides, he said.

Product Pipeline and Launch Plans

Saccaro said Zoetis expects to launch the recently approved Cytopoint Plus in the first quarter. He described the injectable dermatology treatment as lasting 75 days, an extension over the company’s existing offering. Zoetis also expects approval shortly for Simparica Duo, a parasiticide offering, he said.

Beyond its existing franchises, the company is developing products in areas including chronic kidney disease, oncology, anxiety and cardiology. Saccaro estimated the potential market for chronic kidney disease at $3 billion to $4 billion and the oncology market at $1 billion to $2 billion.

He said Cytopoint Plus would begin contributing to results in 2027, while chronic kidney disease could have an impact in 2028 and oncology in later years. Zoetis is not counting on a large contribution from innovation in 2027, he said, with more substantial effects expected as launches accumulate in 2028 and beyond.

Spending and Capital Returns

Saccaro said Zoetis plans to continue funding research and development and capital expenditures while maintaining cost discipline. He described potential acquisitions as generally more likely to be smaller, tuck-in deals than substantial transactions.

Zoetis repurchased $500 million in shares during the third quarter and had returned more than $2 billion to shareholders through buybacks and dividends so far during the year, he said. The company also intends to maintain or grow its dividend and continue buybacks, he said.

On costs, Saccaro said third-quarter selling, general and administrative expenses were flat, and that Zoetis would continue pursuing manufacturing productivity and spending efficiencies. He did not announce a formal savings target.

About Zoetis (NYSE:ZTS)

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.